Enzymotherapy of toxic anterior segment syndrome after phacoemulsification

Cover Page

Abstract


Purpose. To investigate the efficacy of recombinant prourokinase (RPU) treatment in patients with toxic anterior segment syndrome after phacoemulsification.

Material and methods. We observed 123 patients (123 eyes) with toxic anterior segment syndrome after phacoemulsification; patients of the group I (n = 30) received only antiinflammatory treatment; in treatment of patients of the group II (n = 31), instillations of the RPU solution were used, in the group III (n = 31), RPU solution was injected subconjunctivally, in the group IV (n = 31) – RPU solution electrophoresis was used. Treatment result analysis was carried out within 30 days.

Results. Initial mean visual acuity in groups was 0.09 ± 0.04; 0.1 ± 0.04; 0.09 ± 0.04; 0.08 ± 0.04, and was virtually the same (p > 0.05). In 24 hours after treatment initiation, mean visual acuity in the group III was higher, than in the others. In three days and up to the end of observation period, the lowest mean visual acuity was noted in the group I (p < 0.05). Anterior chamber assessment showed that beginning from the first 24 hours after treatment initiation, in groups III and IV, fibrin lysis in the anterior chamber was more pronounced, than in groups I and II (p < 0.05); by the end of the observation period, worst indices of anterior chamber state were found in the group I (p < 0.05), in other groups, they were almost identical (p < 0.05). When using RPU, no allergic reaction was noted.

Conclusions. RPU use in combined toxic anterior segment syndrome therapy after phacoemulsification allows increasing visual acuity, reducing convalescence time, and reducing the number of laser dissections. It was established that all methods of RPU administration are effective. RPU may be administered as eye drops on an outpatient basis, receiving efficacy similar to other administration methods.


Alexander S Suvorov

Author for correspondence.
mr.Suvorov-08.04.88@mail.ru
S.M. Kirov Military Medical Academy
Russian Federation, Saint Petersburg, Russia

MD, aspirant. Ophthalmology Department

Timur G Sazhin

mma.ophth@mail.ru
S.M. Kirov Military Medical Academy
Russian Federation, Saint Petersburg, Russia

MD, PhD, assistant. Ophthalmology Department

  • Белогуров А.А., Бибилашвили Р.Ш., Горюнова Л.Е. Рекомбинантная плазмидная ДНК ривс, кодирующая активатор плазминогенеза урокиназного типа, способ её конструирования и штамм бактерии Е. coli: Пат. 162151, А 61КРФ 1993 // Вестн. офтальмологии. – 1998. – № 1. – C.10–11. [Belogurov AA, Bibilashvili RSh, Goryunova LE. Rekombinantnaya plazmidnaya DNK rivs, kodiruyushchaya aktivator plazminogeneza urokinaztsogo tipa, sposob ee konstruirovaniya i shtamm bakterii E. coli: Pat. 162151, A 61KRF 1993. Vestn. oftal’mologii. 1998;(1):10-11. (In Russ.)]
  • Бойко Э.В., Даниличев В.Ф., Кольцова С.В. Экспериментальное обоснование применения рекомбинантной проурокиназы и её иммобилизированных форм для лечения послеоперационного фибриноидного синдрома в офтальмологии // Бюллетень экспериментальной биологии и медицины. – 1997. – Т. 123. – № 2. – С. 201–204. [Boyko EV, Danilichev VF, Kol’tsova SV. Eksperimental’noe obosnovanie primeneniya rekombinantnoy prourokinazy i ee immobilizirovannykh form dlya lecheniya posleoperatsionnogo fibrinoidnogo sindroma v oftal’mologii. Byulleten’ eksperimental’noy biologii i meditsiny. 1997;123(2):201-204. (In Russ.)]
  • Бочаров В.Е., Иванов М.Н., Двали М.Л., и др. Системное применение кортикостероидов для предупреждения фибринозного иридоциклита при артифакии // Вестн. офтальмологии. – 1993. – № 2. – С. 17–19. [Bocharov VE, Ivanov MN, Dvali ML, et al. Sistemnoe primenenie kortikosteroidov dlya preduprezhdeniya fibrinoznogo iridotsiklita pri artifakii. Vestn. oftal’mologii. 1993;(2):17-19. (In Russ.)]
  • Логай И.М., Леус Н.Ф., Георгиев Д.Д. Эффективность селективных ингибиторов синтеза простогландинов и лейкотриенов в снижении воспалительной реакции после экстракапсулярной экстракции катаракты с имплантацией ИОЛ // Офтальмологический журнал. – 2002. – № 3. – С. 22–27.[Logay IM, Leus NF, Georgiev DD. Effektivnost’ selektivnykh ingibitorov sinteza prostoglandinov i leykotrienov v snizhenii vospalitel’noy reaktsii posle ekstrakapsulyarnoy ekstraktsii katarakty s implantatsiey IOL. Oftal’mologicheskiy zhurnal. 2002;(3):22-27. (In Russ.)]
  • Логай И.М., Леус Н.Ф. Селективные ингибиторы синтеза простагландинов // Офтальмологический журнал. – 1999. – № 4. – С. 286–293. [Logay IM, Leus NF. Selektivnye ingibitory sinteza prostoglandinov. Oftal’mologicheskiy zhurnal. 1999;(4):286-293. (In Russ.)]
  • Нарбут Н.П., Нуриева С.М. Эффективность применения ферментов в лечении токсикоаллергических реакций после экстракции катаракты с имплантацией интраокулярных линз // Вестн. офтальмологии. – 1998. – № 5. – С. 21–23. [Narbut NP, Nurieva SM. Effektivnost’ primeneniya fermentov v lechenii toksikoalergichskikh reaktsiy posle ekstraktsii katarakty s implantatsiey intrаokulyarnykh linz. Vestn. oftal’mologii. 1998;(5):21-23. (In Russ.)]
  • Полунин Г.С. Показания и способы ферментотерапии в офтальмологической практике: Автореф. дис. … д-ра мед. наук. – М., 1990. – с. 8. [Polunin GS. Pokazaniya i sposoby fermentoterapii v oftal’mologicheskoy praktike. [dissertation] Moscow; 1990. p. 8 (In Russ.)]
  • Aaberg TM, Flynn HW, Schiffman J, et al. Nosocomial acute onset postoperative endophthalmitis survey. Ophthalmology.1998;105:1004-1010.
  • Cole DF, Unger WG. Proceedings: The involvement of prostaglandin in ocular trauma. Exp Eye Res. 1973;17:357-368. doi: org/10.1016/0014-4835(73)90245-5.
  • Davis BL, Kearsley L, Mamalis N. Postoperative endophthalmitis vs. Toxic Anterior Segment Syndrome. Ophthalmic hyperguide. Available at: http://www.ophthalmic.hyperguides.com. Accessed October, 2002.
  • Bodnar Z, Clouser S, Mamalis N. Toxic anterior segment syndrome: Update on the most common causes. J Cataract Refract Surg. 2012Nov;38(11):1902-1910. doi: 10.1016/j.jcrs.2012.06.053.
  • Jehan FS, Mamalis N, Spencer TS, et al. Postoperative sterile endophthalmitis (TASS) associated with the Memory Lens. J Cataract Refract Surg. 2000;26:1773-1777. doi: 10.1016/S0886-3350(00)00726-4.
  • Cutler Peck CM, Brubaker J, Clouser S, et al. Toxic anterior segment syndrome: common causes. J Cataract Refract Surg. 2010Jul;36(7):1073-1080. doi: 10.1016/j.jcrs.2010.01.030.
  • Hellinger WC, Hasan SA, Bacalis LP, et al. Outbreak of toxic anterior segment syndrome following cataract surgery associated with impurities in autoclave steam moisture. Infect Control Hosp Epidemiol. 2006;27:294-298. doi: 10.1086/501540.
  • Unal M, Yucel I, Akar Y, Oner A, Altin M. Outbreak of toxic anterior segment syndrome associated with glutaraldehyde after cataract surgery. J Cataract Refract Surg. 2006;32;1696-1701. doi: 10.1016/j.jcrs.2006.05.008.
  • Werner L, Sher JH, Taylor JR, et al. Toxic anterior segment syndrome and possible association with ointment in the anterior chamber following cataract surgery. J Cataract Refract Surg. 2006;32:227-235. doi: 10.1016/j.jcrs.2005.12.093.
  • Preud’homme Y, Demolle D, Boeynaems JM. Metabolism of arachidonic acid in rabbit iris and retina. Invest Ophthalmol Vis Sci. 1985;26:1336-1342.

Views

Abstract - 38

PDF (Russian) - 49


Copyright (c) 2017 ECO-vector LLC

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.